Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...

Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care ...

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Despite efforts to try to get this medication for free, Angela has to pay for it privately because the National Institute for Health and Care Excellence (NICE) says she is not eligible.

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

The updated guidelines from American Society for Radiation Oncology also address the treatment of older and medically frail ...

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four ...

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

Cardiff Oncology's onvansertib shows a 64% response rate in early colorectal cancer trials. Click here to read an analysis of ...

Domestic researchers have found for the first time in the world that immuno-cancer drugs atetzolizumab plus bevacizumab ...

Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ...

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.